Form 8-K - Current report:
SEC Accession No. 0001837607-24-000017
Filing Date
2024-03-29
Accepted
2024-03-29 16:16:23
Documents
18
Period of Report
2024-03-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20240329x8k.htm   iXBRL 8-K 45497
2 EX-99.1 aeon-20240329xex99d1.htm EX-99.1 14502
3 EX-99.2 aeon-20240329xex99d2.htm EX-99.2 28678
4 GRAPHIC aeon-20240329xex99d1001.jpg GRAPHIC 3801
  Complete submission text file 0001837607-24-000017.txt   293829

Data Files

Seq Description Document Type Size
5 EX-101.SCH aeon-20240329.xsd EX-101.SCH 4361
6 EX-101.DEF aeon-20240329_def.xml EX-101.DEF 14402
7 EX-101.LAB aeon-20240329_lab.xml EX-101.LAB 16785
8 EX-101.PRE aeon-20240329_pre.xml EX-101.PRE 14790
21 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240329x8k_htm.xml XML 7177
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 24804298
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)